Now that Kythera Biopharmaceuticals Inc. has granted rights for ATX 101 to Intendis, a Bayer HealthCare company, in a deal potentially worth $373 million, the landscape for fat reduction drugs is expanding beyond therapeutic obesity indications and into the lucrative aesthetics market. Body shaping technologies are one of the fastest-growing sectors of that rapidly expanding market. (BioWorld Today) Read More
